Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Accrol Group Holdings Plc LSE:ACRL London Ordinary Share GB00BZ6VT592 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -3.91% 61.50 324,150 15:39:30
Bid Price Offer Price High Price Low Price Open Price
61.00 62.00 66.00 61.50 64.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Household Goods & Home Construction 134.77 -1.89 -0.80 191
Last Trade Time Trade Type Trade Size Trade Price Currency
16:33:45 O 10,000 63.00 GBX

Accrol (ACRL) Latest News

More Accrol News
Accrol Investors    Accrol Takeover Rumours

Accrol (ACRL) Discussions and Chat

Accrol Forums and Chat

Date Time Title Posts
20/1/202115:12*** Accrol ***780
09/12/202011:03Accrol Papers (ACRL) Manufacturers of Soft Tissue Products3
20/6/201606:24Accrol Papers (ACRL) cleans up on AIM debut1

Add a New Thread

Accrol (ACRL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Accrol trades in real-time

Accrol (ACRL) Top Chat Posts

DateSubject
23/1/2021
08:20
Accrol Daily Update: Accrol Group Holdings Plc is listed in the Household Goods & Home Construction sector of the London Stock Exchange with ticker ACRL. The last closing price for Accrol was 64p.
Accrol Group Holdings Plc has a 4 week average price of 57p and a 12 week average price of 44.50p.
The 1 year high share price is 75p while the 1 year low share price is currently 27p.
There are currently 311,354,632 shares in issue and the average daily traded volume is 650,196 shares. The market capitalisation of Accrol Group Holdings Plc is £191,483,098.68.
18/1/2021
13:23
bb123: Any views to share from watching the Podcast: Https://www.piworld.co.uk/podcasts/ ???
18/1/2021
12:19
tomps2: Here's the ACRL presentation with Q&A from Friday (15.1.21) Video: Https://www.piworld.co.uk/2021/01/18/accrol-group-acrl-interim-results-presentation-january-2021/ Podcast: Https://www.piworld.co.uk/podcasts/
14/1/2021
10:33
tomps2: ACRL results webinar tomorrow on piworld, when you can ask any questions. Register here: Https://www.piworld.co.uk/events/
14/1/2021
07:21
this_is_me: It looks like the selling after the results were the result of bosses selling enough shares to pay the tax on their share awards.
12/1/2021
12:08
leadersoffice: Not bothered at all by price action today. Obviously was climbing in anticipation of results. Maybe there was a leak? wouldn't be the first time. As long as it stays over 59p
12/1/2021
07:50
albanyvillas: Zeus-We remain highly confident that Accrol will emerge as a £35-40m EBITDA business with minimal debt and above average growth, which could equate to an equity value of c.£400m (c122p per share)...
14/12/2020
09:02
this_is_me: The share price has been on an upward trend for two years. Today's rise is just a continuation of that trend which has seen the share price just about triple in that time leaving me very happy. Plenty more to come in the next two years.
13/12/2020
13:54
mfhmfh: ACRL had 8 tissue lines at maximum capacity. The company they have recently acquired has 4 tissue lines bit only 2 being used fully. When ACRL have the other 2 lines being used they will increase their capacity by 50% and have cost savings. All IMHO.
13/12/2020
07:51
simon gordon: Came across ACRL via this Gervais Williams interview - starts 40.45: Vox Markets - 24/11/20 Https://www.voxmarkets.co.uk/articles/gervais-williams-of-premier-miton-offers-and-update-on-his-portfolio-9827b33/
23/11/2020
09:34
davebowler: Zeus; Transformational deal We believe Accrol’s acquisition of LTC represents a transformational transaction which the potential to consolidate the Group’s leading position in the private label tissue market to c.30% share. On completion of the deal, the Group’s combined customer base will be stronger and broader with a step change in capacity to further accelerate its already impressive growth which continues to outpace the market. We estimate the acquisition to be 14.2% EPS enhancing in FY22E the first full year of ownership. The core Accrol business continues to trade solidly, driving an additional upgrade to our underlying numbers today. We believe Accrol’s established platform can deliver an market capitalisation of £400m+ over the medium term. § Acquisition overview: Accrol announced the acquisition of Leicester Tissue Company (LTC) on 2nd November, supplemented by a primary placing to raise £38.5m and an open offer raising £4.1m. The enlarged group will have c.£220m of combined revenue capacity, encompassing 12 tissue and 2 facial converting lines and c390 employees. § Key benefits: LTC is an established and well invested tissue converter with an impressive financial track record (70% revenue CAGR 2017-19), which we believe speaks for itself. LTC brings four high quality tissue conversion lines all under six years old to the Group, taking combined revenue capacity to c.£220m and enabling Accrol to defer £5.0m of capex spend from FY21 into FY22. The acquisition of LTC takes the Group’s private label market share from c26% pre acquisition to c30% post acquisition. We believe Accrol has paid less than 5x LTC’s FY22E EBITDA (post £1.0m anticipated synergies), which represents an attractive price for a strategically important transaction. § Forecasts: Our revised forecasts include an upgrade to the underlying Accrol business which has traded solidly in recent months. The acquisition should be c.14.2% EPS enhancing to our FY22E EPS forecast in the first full year of ownership on what we believe are conservative assumptions. This equates to less than 5x LTC’s 12m forward EBITDA which represents an attractive price for a strategically important transaction in our view. Cost synergies of £1.0m have been identified, which we believe is conservative, with no revenue synergies currently assumed throughout our forecast period. § Investment view: In our view Accrol deserves to trade at least in line, if not at a premium to its peers given its solid growth momentum. A rerating of the shares to 16x-18x FY22E PE over the next 12 months implies a share price of 69-78p. Ultimately we believe Accrol should emerge as a £35m-£40m EBITDA business (£22.5m-£30.0m previously assumed) with minimal debt and above average growth in the ever-expanding discount sector, which we believe could equate to an equity value of c.£400m (c.122p per share) over the medium term.
Accrol share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ACRL
Accrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210124 03:40:49